Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3847275 | 0.92 | S1PR1 (0.58) | S1PR1S1PR3FFAR4ADRA1DADRA1A | |
| SCHEMBL3854586 | 0.91 | S1PR1 (0.50) | S1PR1S1PR3FFAR4FFAR1AR | |
| SCHEMBL3850676 | 0.89 | S1PR1 (0.51) | S1PR1FFAR4FFAR1ADRA1DADRA1A | |
| SCHEMBL3847487 | 0.88 | S1PR1 (0.53) | S1PR1S1PR3FFAR4ADRA1DADRA1A | |
| SCHEMBL3849903 | 0.87 | S1PR1 (0.58) | S1PR1S1PR3FFAR4FFAR1ADRA1D | |
| SCHEMBL13713817 | 0.87 | S1PR1 (0.49) | S1PR1FFAR4FFAR1ADRA1DADRA1A | |
| SCHEMBL3853711 | 0.85 | S1PR1 (0.53) | S1PR1S1PR3FFAR4FFAR1HRH3 | |
| SCHEMBL3847399 | 0.84 | S1PR1 (0.48) | S1PR1S1PR3FFAR4FFAR1AR | |
| SCHEMBL3852741 | 0.83 | S1PR1 (0.53) | S1PR1S1PR3FFAR4FFAR1 | |
| SCHEMBL3847503 | 0.83 | S1PR1 (0.48) | S1PR1S1PR3FFAR4ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | claimed |
| EP-1718307-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-04-29 | — | — | EP | claimed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | claimed |
| EP-1718307-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2006-11-08 | — | — | EP | claimed |
| WO-2005082089-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2005-09-09 | — | — | WO | claimed |
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | disclosed |
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | disclosed |
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | disclosed |
| EP-1718307-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-04-29 | — | — | EP | disclosed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| EP-1718307-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082089-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR3 142/4885FFAR4 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.